We would love to hear your thoughts about our site and services, please take our survey here.
because there is no actual concrete news till summer. presentation was good but more 'potential. No actual news till summers means sp will decline as people on AIM are inpatient and chase the next hype before the merry-go-round returns to avacta. Simples. easy 5k I made today.
I agree. there's upto 100-150 other presentations across the 5 days from other biotechs. Personally I feel yes it may show data is good so far however the company is issuing an RNS for presenting at a conference. well established biotechs don't issue an rns over such small moves. I ge the feeling they are looking for funding/ partners which in essence equals dilution. Not denying the science etc but the company has to seek funding. A runway of around 14-18 months at max
last week I got questioned for selling out at 73p as one thing AIM has taught me is any periods of no major news the sp drops dramatically. LFT has been sidelined and AS doesn't give the lft opportunity the importance he used to. Remember him posting videos on how an LFT works and uptodate guidelines from the goverments. The ava6k phase 1 data will be released mid summer and the question I have is where is the money going to come from for the phase 2 trials and the second IND filing. I took a small loss but this was sub 20p before covid I see those levels in a month. I thought it would hold the 50s but 1 week later were looking shaky. Will probably get hate for this but its been a tormentous 2 years holding and this is a public forum where opinions should be expressed. No bull ramps. Was expecting atleast some data for ava6k this Quarter but got my waffle so this was expected
Let me first clarify i support what the company is doing and yes ' See' the potential and what ava6000 could mean for oncology as a whole. I worked at one of the lead oncology hospitals in the UK within clinical trials and know doxorubicin well. However putting my investor/ trader hat on i have learnt the ceo is prone to mistakes which he has a history of repeating and the past 2 years have shown he has a habit of missing put crucial information.
There was no RNS when ADC therapeutics pulled the plug what is there to say some of the partnerships like moderna haven't done the same we haven't heard from them in a while. Whilst I acknowledge the LG chem deal is big they were potentially starting a in human trial in the summer of 2022 using affirmers. Point biopharma are small fry at an early stage biotech so how much of a development with them would impact the sp.
Looking at other biotechs on aim sentiment is similar the sp drops during 'lull' periods.
if I sold at 73p and re entered in the 50/60s I have increased my holding by 20-30 percent. we are a long way from being bought out so these ramps of takeover are nonsense. Yes we may have 1 or 2 small inflection points but knowing the history of AS a surprise placing is not off the cards. We DO need funds to carry Ava6k to P2 and the other AVA trials. I will take my chances if we are destined to be bought out at £50 a share what difference does it make if I buy back in at £1. however the risk to reward is greater by keeping my money i cash till the dust settles and we have some interims. we have an increased Jupiter short and who knows what the next variant will throw up for our sovereign test.
Personally Sold at 73p. Issue for me is the lack of near term catalysts. Knowing Aim any sort of lull period is punished and SP may drop to 50/60p over the next month. Will look for re entry. don't get me wrong I have studied and learnt about the tech, I have personally worked in clinical trials but the 'Market Sentiment' is what drives alot of AIM stocks is what i have learnt. I could be wrong but hey ho I am fairly confident I will have a lower re entry. company is no where near a takeover and just want some solid information. No more waffle.
I have to Agree. Affirmed tech might be amazing and in the future could be a blockbuster but regardless even the most significant optimist must admit you can't trust AS.
1. 4 weeks on from a dreadful RNS we are STILL searching for a replacement antibody which was not made clear to us in the past 20 months that an antibody was even used in combination.
2. Q1 PK results were promised since August 21 and not its been pushed back to Summer 2022
3. One of the benefits of affirmed is the adaptability of them to new variants. Well..he's known since December and still looking for him to showcase this.
4. Where are out Apac region discussions? Where is the 30m capacity abroad. Are you telling me an order worth a few hundred million from an apac region even if the tests doesn't fully detect omicron should be passed up on for the sake of perfection.
No rose tinted glasses here. A holder I am but not by choice.
personally I think its a valid point. AS said ramping upto 5m by the end of Q3. that range has dropped to 2-3million?
Furthermore he was in *advanced* stage talks with the foreign manufacturers to provide 30m a month. I get the excitement around AvA6k however whatever you want to call the last 18months (ramping, delusion, incompetency, mismanagement of expectations..) for the logical investors has shown AS is not perfect and everything he says should be taken with a pinch of salt. He was talking to airlines 3 months ago, many distributors, Foreign governments you would expect with the urgency of a pandemic he would have pre signed or committed orders by now. I hold regardless but that's because I Invested what I am willing to loose and do not need for the foreseeable future.
https://www.chemistanddruggist.co.uk/news/could-pharmacy-collect-be-risk-fda-recalls-innova-tests-us